Improving treatment for diffuse large B‑cell lymphoma (DLBCL)
Project 4 Green-Davis
['FUNDING_P01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11167656
This project looks for more precise treatments for people with diffuse large B‑cell lymphoma, especially the ABC subtype that often resists standard chemoimmunotherapy, by studying B‑cell signaling and CREBBP-related gene changes.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11167656 on ClinicalTrials.gov |
What this research studies
Researchers are focusing on the biology that drives the aggressive ABC subtype of DLBCL, including chronic B‑cell receptor (BCR) signaling and NFκB pathway activity. They are studying mutations in CREBBP, a gene that controls acetylation of histones and influences genes linked to B‑cell activation, to see how those changes affect tumor behavior. The team uses gene expression profiling and molecular experiments to identify biomarkers and molecular vulnerabilities. The goal is to link those findings to treatments that could be directed to patients with the matching tumor features.
Who could benefit from this research
Good fit: People diagnosed with diffuse large B‑cell lymphoma, particularly the activated B‑cell (ABC) subtype or those whose disease has relapsed or not responded to standard chemoimmunotherapy, would be the ideal candidates.
Not a fit: Patients with other types of cancer or with DLBCL of the germinal center B‑cell (GCB) subtype without CREBBP-related changes may be less likely to benefit from therapies focused on ABC‑DLBCL and CREBBP pathways.
Why it matters
Potential benefit: If successful, this work could enable more personalized therapy for DLBCL patients and identify new treatment targets for those who do not respond to current standard care.
How similar studies have performed: Drugs targeting B‑cell receptor signaling have helped some patient groups, but using CREBBP-related biomarkers to guide therapy is a newer approach and remains largely unproven clinically.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GREEN, MICHAEL RICHARD — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: GREEN, MICHAEL RICHARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.